{"id":"solifenacin-po","safety":{"commonSideEffects":[{"rate":"11-27%","effect":"Dry mouth"},{"rate":"9-15%","effect":"Constipation"},{"rate":"5-8%","effect":"Blurred vision"},{"rate":"1-2%","effect":"Urinary retention"},{"rate":"2-4%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1200803","moleculeType":"Small molecule","molecularWeight":"480.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Solifenacin selectively blocks M3 muscarinic acetylcholine receptors on the detrusor muscle of the bladder, reducing involuntary contractions and increasing bladder capacity. This anticholinergic action decreases urinary frequency, urgency, and incontinence episodes associated with overactive bladder syndrome.","oneSentence":"Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:44.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"}]},"trialDetails":[{"nctId":"NCT05490082","phase":"PHASE3","title":"Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2022-03-01","conditions":"Voiding Disorders","enrollment":100},{"nctId":"NCT00821184","phase":"PHASE3","title":"Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder","status":"TERMINATED","sponsor":"Lahey Clinic","startDate":"2006-09","conditions":"Overactive Bladder","enrollment":12},{"nctId":"NCT00773552","phase":"PHASE4","title":"Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder","status":"WITHDRAWN","sponsor":"Stamford Hospital","startDate":"2008-11","conditions":"Urinary Urge, Urge Incontinence, Overactive Bladder","enrollment":""},{"nctId":"NCT00584090","phase":"PHASE4","title":"Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease","status":"WITHDRAWN","sponsor":"University of South Florida","startDate":"2007-11","conditions":"Urinary Incontinence, Parkinson's Disease","enrollment":""},{"nctId":"NCT00826527","phase":"PHASE4","title":"Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)","status":"UNKNOWN","sponsor":"Seattle Urology Research Center","startDate":"2007-01","conditions":"Urinary Frequency, Urinary Urgency, Nocturia","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Solifenacin PO","genericName":"Solifenacin PO","companyName":"Seattle Urology Research Center","companyId":"seattle-urology-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Solifenacin is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder. Used for Overactive bladder with symptoms of urge incontinence, urgency, and frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}